Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Breast Cancer, HER2”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05044988
What this trial is testing

HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

Who this might be right for
HR+/HER2- Advanced and/or Metastatic Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06172127
What this trial is testing

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
MedSIR 165
Testing effectiveness (Phase 2)Looking for participantsNCT06516289
What this trial is testing

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Who this might be right for
BRCA-Mutated Breast CarcinomaHER2-negative Breast Cancer
Fudan University 130
Testing effectiveness (Phase 2)Looking for participantsNCT06254690
What this trial is testing

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 102
Large-scale testing (Phase 3)Study completedNCT03337724
What this trial is testing

Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 579
Large-scale testing (Phase 3)UnknownNCT03500380
What this trial is testing

RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Who this might be right for
Breast NeoplasmsBreast DiseasesCapecitabine+3 more
RemeGen Co., Ltd. 301
Testing effectiveness (Phase 2)Study completedNCT04300790
What this trial is testing

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Who this might be right for
Breast Cancer
MedSIR 69
Testing effectiveness (Phase 2)WithdrawnNCT01479179
What this trial is testing

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07767474
What this trial is testing

Evaluate ATX-898 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Antares Therapeutics, Inc 343
Testing effectiveness (Phase 2)WithdrawnNCT05371860
What this trial is testing

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Armando Giuliano
Not applicableLooking for participantsNCT07358182
What this trial is testing

Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer

Who this might be right for
Trastuzumab-rezetecanHER2-low Breast CancerHER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Testing effectiveness (Phase 2)Ended earlyNCT05583110
What this trial is testing

Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
HER2-positive Metastatic Breast CancerLocally Advanced HER2 Positive Breast Carcinoma
Spanish Breast Cancer Research Group 13
Not applicableStudy completedNCT00612560
What this trial is testing

Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics

Who this might be right for
Breast Cancer
Roswell Park Cancer Institute 28
Testing effectiveness (Phase 2)Study completedNCT01973660
What this trial is testing

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 151
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06462079
What this trial is testing

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

Who this might be right for
Brain Metastasis
Guangzhou Medical University 43
Testing effectiveness (Phase 2)Study completedNCT01904903
What this trial is testing

Cardiac Safety Study in Patients With HER2 + Breast Cancer

Who this might be right for
HER2 Positive Breast CancerLeft Ventricular Function Systolic Dysfunction
Medstar Health Research Institute 31
Testing effectiveness (Phase 2)Study completedNCT01432223
What this trial is testing

Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab

Who this might be right for
Breast CancerHER-2 Positive Breast CancerEffects of Chemotherapy
Osaka Medical College 46
Not applicableActive Not RecruitingNCT07710716
What this trial is testing

A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 3,000
Not applicableUnknownNCT03947736
What this trial is testing

Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR

Who this might be right for
Recurrent or Metastatic Breast Cancer
Chinese Academy of Medical Sciences 200
Testing effectiveness (Phase 2)Study completedNCT05659563
What this trial is testing

Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%

Who this might be right for
Breast CancerBreast Cancer, Early-Onset
MedSIR 92
Next Page